Sustainability & Climate

Alterra's 26/27 Ikon Pass introduces a game-changing refund policy, expands into the Midwest, and adds new lifestyle perks in a bold competitive move.

With its new FRESHPREY line, premium brand ORIJEN challenges fresh food incumbents, leveraging extreme marketing and a 'WholePrey' philosophy.

As AI adoption outpaces oversight, Check Point’s new advisory service aims to help enterprises manage risk and navigate complex new regulations like the EU AI Act.

The pet care giant is leveraging its massive platform to connect owners with vetted trainers, aiming to become the go-to resource for all pet needs.

Newly published research brings scientific rigor to the controversial kratom plant, influencing policy from the FDA to statehouses across the nation.

FOTRIC's new TK6Kit bundles a true 384x288 thermal camera with a full set of field gear for just $949, making professional-grade inspections accessible.

With a 30-year operations veteran retiring, Delta promotes a new president, COO, and CFO, betting on internal talent to navigate its future growth.

A new Chinese fantasy drama personifies ancient instruments into living spirits. Here's how 'The Melody of Love' is set to change global entertainment.

As burnout plagues radiology, Fujifilm unveils AI workflow solutions at HIMSS 2026 aimed at easing workloads and boosting hospital efficiency.

New study shows an AI platform matches expert radiologists in tumor measurement, promising a new era of precision and consistency in breast cancer surgery.

With FDA Breakthrough status for its MASH drug, a new CEO, and a fortified balance sheet, Altimmune is poised to take on serious liver disease and addiction.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With a new outpatient model, NexCure aims to bring life-saving cancer treatments like CAR-T closer to home, tackling a major healthcare bottleneck.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Early data for zolucatetide shows it shrinks tumors in a rare genetic disease, cracking a long-undruggable cancer target and offering new hope.

Seven Colombian designers are captivating Paris Fashion Week, weaving ancestral craft and modern style into a strategic play for global economic recognition.

Phonak's new hearing aids won a top design award, blending advanced AI with discreet style to change how we see and hear with assistive technology.

Vermilion Energy boosts its dividend for the fifth straight year, a move backed by strong cash flow and a strategic focus on premium gas markets.